FDA record · warning letter

FDA warning letter: US Chem Labs (Feb 7, 2024)

On Feb 7, 2024, FDA issued a warning letter to US Chem Labs of Miami, FL under the subject "CGMP/Finished Pharmaceuticals/Adulterated". It names semaglutide, tirzepatide. Open: no closeout letter published as of Oct 3, 2026.

Julian CaraulaniFounder, PriceTracker GLP-1FDA record read Oct 3

Status: Open: no closeout letter published as of Oct 3, 2026.

What FDA’s record states

FDA record for the warning letter to US Chem Labs
Field	What FDA’s record states	Source
Recipient	US Chem Labs	FDA letter
Location	Miami, FL	FDA letter
Letter date	Feb 7, 2024	FDA letter
Posted by FDA	Feb 13, 2024	FDA index
Issuing office	Center for Drug Evaluation and Research \| CDER	FDA letter
Subject	CGMP/Finished Pharmaceuticals/Adulterated	FDA letter
MARCS-CMS number	669074	FDA letter
GLP-1 drugs named	Semaglutide, Tirzepatide	FDA letter
Response letter	Not published by FDA	FDA letter
Closeout letter	Not published by FDA	FDA letter

“This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website at the Internet address www.uschemlabs.com in October 2023 and has observed that your website offers “Semaglutide,” “Tirzepatide” and “Thymalin” products for sale in the United States.”FDA warning letter to US Chem Labs, Feb 7, 2024 · read the full letter on fda.gov ↗

What this is and is not.A warning letter is FDA’s statement of what it considers significant violations. It is an allegation, not a court finding, and the firm can respond. A closeout letter is posted when FDA confirms the violations were corrected.

Other GLP-1 letters FDA issued that week

Source

Every field above is copied from FDA’s page for this letter, read Oct 3, 2026. The letter on fda.gov ↗ · All 161 GLP-1 warning letters